Regeneron’s Saratoga Springs Site Gains FDA PreCheck Status to Cut 14-Month Review
REGN•FDA selected Regeneron’s Saratoga Springs facility for its PreCheck pilot, enabling regulator reviews during construction and potentially cutting approval timelines by up to 14 months. The site will produce biologic drug substance, protein therapeutics and sterile injectables, boosting near-term manufacturing capacity for Regeneron’s pipeline.
1. FDA PreCheck Pilot Overview
The FDA launched the PreCheck Pilot Program on February 1, 2026 under a 2025 executive order to accelerate reviews of new domestic pharmaceutical facilities. Seven companies were chosen from over 80 applicants, granting technical input, early inspections and faster assessments that could shorten approval timelines by as much as 14 months.
2. Regeneron’s Saratoga Springs Facility Details
Regeneron’s new site in Saratoga Springs, New York will produce biologic drug substance, protein therapeutics and sterile injectable products. Inclusion in the pilot allows the company to submit construction-phase data via a Drug Master File and secure pre-submission meetings before the facility goes live.
3. Potential Impact on Regeneron
Accelerated facility approval can enable Regeneron to bring pipeline candidates and existing biologics to market more quickly and reduce manufacturing delays. Earlier regulator engagement may also lower compliance risk and support smoother scale-up of production capacity for future therapies.
